Skip to main content
. Author manuscript; available in PMC: 2018 Sep 20.
Published in final edited form as: Curr Neurol Neurosci Rep. 2017 Sep 20;17(11):85. doi: 10.1007/s11910-017-0796-0

Fig. 2.

Fig. 2

Differential efficacy of adjunctive dexamethasone among tuberculous meningitis patients based on LTA4H promoter genotype (Reprinted from Cell, Vol 148(3), David M. Tobin, Francisco J. Roca, Sungwhan F. Oh, Ross McFarland, Thad W. Vickery, John P. Ray, Dennis C. Ko, Yuxia Zou, Nguyen D. Bang, Tran T.H. Chau, Jay C. Vary, Thomas R. Hawn, Sarah J. Dunstan, Jeremy J. Farrar, Guy E. Thwaites, Mary-Claire King et al., Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections, Pages No. 434–46, Copyright (2012), with permission from Elsevier). a Effect of adjunctive dexamethasone on survival across all genotypes. b Survival of patients not treated with dexamethasone, stratified by LTA4H promoter genotype. c Survival of patients treated with dexamethasone, stratified by LTA4H promoter genotype